nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanfacine—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0984	0.143	CbGbCtD
Guanfacine—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0984	0.143	CbGbCtD
Guanfacine—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0818	0.119	CbGbCtD
Guanfacine—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0818	0.119	CbGbCtD
Guanfacine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0627	0.0914	CbGbCtD
Guanfacine—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.062	0.0903	CbGbCtD
Guanfacine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0424	0.0618	CbGbCtD
Guanfacine—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0413	0.0602	CbGbCtD
Guanfacine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0404	0.0589	CbGbCtD
Guanfacine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.036	0.0525	CbGbCtD
Guanfacine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0211	0.0308	CbGbCtD
Guanfacine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.02	0.0291	CbGbCtD
Guanfacine—Guanabenz—CYP1A2—chronic obstructive pulmonary disease	0.00406	0.493	CrCbGaD
Guanfacine—Diclofenac—CXCL8—chronic obstructive pulmonary disease	0.00192	0.233	CrCbGaD
Guanfacine—Diclofenac—CYP1A1—chronic obstructive pulmonary disease	0.000894	0.109	CrCbGaD
Guanfacine—Diclofenac—CYP1A2—chronic obstructive pulmonary disease	0.000862	0.105	CrCbGaD
Guanfacine—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000626	0.00255	CcSEcCtD
Guanfacine—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000626	0.00255	CcSEcCtD
Guanfacine—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000626	0.00254	CcSEcCtD
Guanfacine—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000624	0.00254	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000622	0.00253	CcSEcCtD
Guanfacine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.00062	0.00252	CcSEcCtD
Guanfacine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.00062	0.00252	CcSEcCtD
Guanfacine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.00062	0.00252	CcSEcCtD
Guanfacine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000619	0.00252	CcSEcCtD
Guanfacine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000617	0.00251	CcSEcCtD
Guanfacine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000613	0.00249	CcSEcCtD
Guanfacine—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000613	0.00249	CcSEcCtD
Guanfacine—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000609	0.00247	CcSEcCtD
Guanfacine—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000609	0.00247	CcSEcCtD
Guanfacine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000608	0.00247	CcSEcCtD
Guanfacine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000601	0.00244	CcSEcCtD
Guanfacine—Affect lability—Prednisolone—chronic obstructive pulmonary disease	0.000598	0.00243	CcSEcCtD
Guanfacine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000597	0.00243	CcSEcCtD
Guanfacine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000597	0.00242	CcSEcCtD
Guanfacine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000597	0.00242	CcSEcCtD
Guanfacine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000592	0.00241	CcSEcCtD
Guanfacine—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000591	0.0024	CcSEcCtD
Guanfacine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000586	0.00238	CcSEcCtD
Guanfacine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000584	0.00237	CcSEcCtD
Guanfacine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000584	0.00237	CcSEcCtD
Guanfacine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000583	0.00237	CcSEcCtD
Guanfacine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000583	0.00237	CcSEcCtD
Guanfacine—Skin exfoliation—Prednisone—chronic obstructive pulmonary disease	0.00058	0.00236	CcSEcCtD
Guanfacine—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000575	0.00234	CcSEcCtD
Guanfacine—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000575	0.00234	CcSEcCtD
Guanfacine—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000575	0.00234	CcSEcCtD
Guanfacine—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000575	0.00234	CcSEcCtD
Guanfacine—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000575	0.00234	CcSEcCtD
Guanfacine—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000575	0.00234	CcSEcCtD
Guanfacine—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000575	0.00234	CcSEcCtD
Guanfacine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000573	0.00233	CcSEcCtD
Guanfacine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000573	0.00233	CcSEcCtD
Guanfacine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000573	0.00233	CcSEcCtD
Guanfacine—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000573	0.00233	CcSEcCtD
Guanfacine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000572	0.00233	CcSEcCtD
Guanfacine—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000572	0.00232	CcSEcCtD
Guanfacine—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000568	0.00231	CcSEcCtD
Guanfacine—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000568	0.00231	CcSEcCtD
Guanfacine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000563	0.00229	CcSEcCtD
Guanfacine—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000563	0.00229	CcSEcCtD
Guanfacine—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000563	0.00229	CcSEcCtD
Guanfacine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000562	0.00228	CcSEcCtD
Guanfacine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000562	0.00228	CcSEcCtD
Guanfacine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000561	0.00228	CcSEcCtD
Guanfacine—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00056	0.00228	CcSEcCtD
Guanfacine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000558	0.00227	CcSEcCtD
Guanfacine—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000551	0.00224	CcSEcCtD
Guanfacine—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000551	0.00224	CcSEcCtD
Guanfacine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.00055	0.00224	CcSEcCtD
Guanfacine—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000543	0.00221	CcSEcCtD
Guanfacine—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000543	0.00221	CcSEcCtD
Guanfacine—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000543	0.00221	CcSEcCtD
Guanfacine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000541	0.0022	CcSEcCtD
Guanfacine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00054	0.00219	CcSEcCtD
Guanfacine—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00054	0.00219	CcSEcCtD
Guanfacine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000538	0.00219	CcSEcCtD
Guanfacine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000538	0.00219	CcSEcCtD
Guanfacine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000536	0.00218	CcSEcCtD
Guanfacine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000533	0.00217	CcSEcCtD
Guanfacine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000531	0.00216	CcSEcCtD
Guanfacine—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.00052	0.00211	CcSEcCtD
Guanfacine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000515	0.00209	CcSEcCtD
Guanfacine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000515	0.00209	CcSEcCtD
Guanfacine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000512	0.00208	CcSEcCtD
Guanfacine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000512	0.00208	CcSEcCtD
Guanfacine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000508	0.00206	CcSEcCtD
Guanfacine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000503	0.00204	CcSEcCtD
Guanfacine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000503	0.00204	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000502	0.00204	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000502	0.00204	CcSEcCtD
Guanfacine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000498	0.00202	CcSEcCtD
Guanfacine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000498	0.00202	CcSEcCtD
Guanfacine—Diclofenac—ALB—chronic obstructive pulmonary disease	0.000498	0.0605	CrCbGaD
Guanfacine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000495	0.00201	CcSEcCtD
Guanfacine—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000493	0.002	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000492	0.002	CcSEcCtD
Guanfacine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000491	0.002	CcSEcCtD
Guanfacine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000491	0.002	CcSEcCtD
Guanfacine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00049	0.00199	CcSEcCtD
Guanfacine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00049	0.00199	CcSEcCtD
Guanfacine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000488	0.00198	CcSEcCtD
Guanfacine—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000486	0.00198	CcSEcCtD
Guanfacine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000486	0.00198	CcSEcCtD
Guanfacine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000485	0.00197	CcSEcCtD
Guanfacine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000485	0.00197	CcSEcCtD
Guanfacine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000485	0.00197	CcSEcCtD
Guanfacine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000483	0.00196	CcSEcCtD
Guanfacine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00048	0.00195	CcSEcCtD
Guanfacine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000479	0.00195	CcSEcCtD
Guanfacine—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000478	0.00194	CcSEcCtD
Guanfacine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000475	0.00193	CcSEcCtD
Guanfacine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000475	0.00193	CcSEcCtD
Guanfacine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000475	0.00193	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000474	0.00193	CcSEcCtD
Guanfacine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000471	0.00191	CcSEcCtD
Guanfacine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000471	0.00191	CcSEcCtD
Guanfacine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000471	0.00191	CcSEcCtD
Guanfacine—Amnesia—Prednisone—chronic obstructive pulmonary disease	0.00047	0.00191	CcSEcCtD
Guanfacine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000467	0.0019	CcSEcCtD
Guanfacine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000465	0.00189	CcSEcCtD
Guanfacine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000464	0.00188	CcSEcCtD
Guanfacine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000463	0.00188	CcSEcCtD
Guanfacine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000461	0.00187	CcSEcCtD
Guanfacine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00046	0.00187	CcSEcCtD
Guanfacine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000459	0.00186	CcSEcCtD
Guanfacine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000458	0.00186	CcSEcCtD
Guanfacine—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000458	0.00186	CcSEcCtD
Guanfacine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000456	0.00185	CcSEcCtD
Guanfacine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000456	0.00185	CcSEcCtD
Guanfacine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000455	0.00185	CcSEcCtD
Guanfacine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000454	0.00184	CcSEcCtD
Guanfacine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000454	0.00184	CcSEcCtD
Guanfacine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000454	0.00184	CcSEcCtD
Guanfacine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000452	0.00184	CcSEcCtD
Guanfacine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000451	0.00183	CcSEcCtD
Guanfacine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000451	0.00183	CcSEcCtD
Guanfacine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000451	0.00183	CcSEcCtD
Guanfacine—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.00045	0.00183	CcSEcCtD
Guanfacine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000449	0.00182	CcSEcCtD
Guanfacine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000445	0.00181	CcSEcCtD
Guanfacine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000441	0.00179	CcSEcCtD
Guanfacine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000436	0.00177	CcSEcCtD
Guanfacine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000436	0.00177	CcSEcCtD
Guanfacine—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000434	0.00176	CcSEcCtD
Guanfacine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000434	0.00176	CcSEcCtD
Guanfacine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00043	0.00175	CcSEcCtD
Guanfacine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00043	0.00175	CcSEcCtD
Guanfacine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00043	0.00175	CcSEcCtD
Guanfacine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000429	0.00174	CcSEcCtD
Guanfacine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000428	0.00174	CcSEcCtD
Guanfacine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000428	0.00174	CcSEcCtD
Guanfacine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000427	0.00173	CcSEcCtD
Guanfacine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000425	0.00173	CcSEcCtD
Guanfacine—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000421	0.00171	CcSEcCtD
Guanfacine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000411	0.00167	CcSEcCtD
Guanfacine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000406	0.00165	CcSEcCtD
Guanfacine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000406	0.00165	CcSEcCtD
Guanfacine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000406	0.00165	CcSEcCtD
Guanfacine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000405	0.00164	CcSEcCtD
Guanfacine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000398	0.00162	CcSEcCtD
Guanfacine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000395	0.00161	CcSEcCtD
Guanfacine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000395	0.00161	CcSEcCtD
Guanfacine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00039	0.00158	CcSEcCtD
Guanfacine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00039	0.00158	CcSEcCtD
Guanfacine—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000389	0.00158	CcSEcCtD
Guanfacine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000387	0.00157	CcSEcCtD
Guanfacine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000383	0.00156	CcSEcCtD
Guanfacine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000382	0.00155	CcSEcCtD
Guanfacine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000377	0.00153	CcSEcCtD
Guanfacine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000377	0.00153	CcSEcCtD
Guanfacine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000373	0.00152	CcSEcCtD
Guanfacine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000369	0.0015	CcSEcCtD
Guanfacine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000368	0.0015	CcSEcCtD
Guanfacine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000364	0.00148	CcSEcCtD
Guanfacine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000364	0.00148	CcSEcCtD
Guanfacine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000357	0.00145	CcSEcCtD
Guanfacine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000356	0.00145	CcSEcCtD
Guanfacine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000351	0.00143	CcSEcCtD
Guanfacine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00035	0.00142	CcSEcCtD
Guanfacine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00035	0.00142	CcSEcCtD
Guanfacine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000347	0.00141	CcSEcCtD
Guanfacine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000347	0.00141	CcSEcCtD
Guanfacine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000347	0.00141	CcSEcCtD
Guanfacine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000347	0.00141	CcSEcCtD
Guanfacine—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000347	0.00141	CcSEcCtD
Guanfacine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000345	0.0014	CcSEcCtD
Guanfacine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000345	0.0014	CcSEcCtD
Guanfacine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000345	0.0014	CcSEcCtD
Guanfacine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000344	0.0014	CcSEcCtD
Guanfacine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000343	0.00139	CcSEcCtD
Guanfacine—Rash—Montelukast—chronic obstructive pulmonary disease	0.00034	0.00138	CcSEcCtD
Guanfacine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00034	0.00138	CcSEcCtD
Guanfacine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000339	0.00138	CcSEcCtD
Guanfacine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000338	0.00137	CcSEcCtD
Guanfacine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000335	0.00136	CcSEcCtD
Guanfacine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000333	0.00135	CcSEcCtD
Guanfacine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000331	0.00134	CcSEcCtD
Guanfacine—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.00033	0.00134	CcSEcCtD
Guanfacine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000328	0.00133	CcSEcCtD
Guanfacine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.00133	CcSEcCtD
Guanfacine—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000328	0.00133	CcSEcCtD
Guanfacine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.00133	CcSEcCtD
Guanfacine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000327	0.00133	CcSEcCtD
Guanfacine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000327	0.00133	CcSEcCtD
Guanfacine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000326	0.00132	CcSEcCtD
Guanfacine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000321	0.00131	CcSEcCtD
Guanfacine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000321	0.0013	CcSEcCtD
Guanfacine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000317	0.00129	CcSEcCtD
Guanfacine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000316	0.00128	CcSEcCtD
Guanfacine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000311	0.00126	CcSEcCtD
Guanfacine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000309	0.00126	CcSEcCtD
Guanfacine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000308	0.00125	CcSEcCtD
Guanfacine—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000304	0.00123	CcSEcCtD
Guanfacine—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000298	0.00121	CcSEcCtD
Guanfacine—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000294	0.00119	CcSEcCtD
Guanfacine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000291	0.00118	CcSEcCtD
Guanfacine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000288	0.00117	CcSEcCtD
Guanfacine—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000285	0.00116	CcSEcCtD
Guanfacine—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000276	0.00112	CcSEcCtD
Guanfacine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.00027	0.0011	CcSEcCtD
Guanfacine—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.00027	0.0011	CcSEcCtD
Guanfacine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000268	0.00109	CcSEcCtD
Guanfacine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.00025	0.00102	CcSEcCtD
Guanfacine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000247	0.001	CcSEcCtD
Guanfacine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000246	0.000999	CcSEcCtD
Guanfacine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000244	0.000992	CcSEcCtD
Guanfacine—Malaise—Prednisone—chronic obstructive pulmonary disease	0.00024	0.000974	CcSEcCtD
Guanfacine—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000239	0.00097	CcSEcCtD
Guanfacine—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000238	0.000968	CcSEcCtD
Guanfacine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000234	0.000949	CcSEcCtD
Guanfacine—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.00023	0.000935	CcSEcCtD
Guanfacine—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000229	0.000932	CcSEcCtD
Guanfacine—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000226	0.000919	CcSEcCtD
Guanfacine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000226	0.000919	CcSEcCtD
Guanfacine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000225	0.000916	CcSEcCtD
Guanfacine—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000223	0.000908	CcSEcCtD
Guanfacine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.00022	0.000893	CcSEcCtD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000218	0.00367	CbGpPWpGaD
Guanfacine—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000217	0.000881	CcSEcCtD
Guanfacine—Shock—Prednisone—chronic obstructive pulmonary disease	0.000213	0.000867	CcSEcCtD
Guanfacine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000212	0.00086	CcSEcCtD
Guanfacine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.00021	0.000852	CcSEcCtD
Guanfacine—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000209	0.00351	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	0.000208	0.00351	CbGpPWpGaD
Guanfacine—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000202	0.00341	CbGpPWpGaD
Guanfacine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000201	0.00339	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet activation, signaling and aggregation—TGFB2—chronic obstructive pulmonary disease	0.000201	0.00339	CbGpPWpGaD
Guanfacine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000198	0.00333	CbGpPWpGaD
Guanfacine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000198	0.000803	CcSEcCtD
Guanfacine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000197	0.000802	CcSEcCtD
Guanfacine—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000196	0.000797	CcSEcCtD
Guanfacine—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000195	0.00329	CbGpPWpGaD
Guanfacine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000195	0.000791	CcSEcCtD
Guanfacine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000191	0.000776	CcSEcCtD
Guanfacine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000188	0.000766	CcSEcCtD
Guanfacine—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000188	0.000764	CcSEcCtD
Guanfacine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000188	0.000764	CcSEcCtD
Guanfacine—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000187	0.00076	CcSEcCtD
Guanfacine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000187	0.00076	CcSEcCtD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000187	0.00315	CbGpPWpGaD
Guanfacine—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000185	0.000753	CcSEcCtD
Guanfacine—ADRA2A—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	0.000181	0.00304	CbGpPWpGaD
Guanfacine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.00018	0.00304	CbGpPWpGaD
Guanfacine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000179	0.000726	CcSEcCtD
Guanfacine—ADRA2A—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.000178	0.003	CbGpPWpGaD
Guanfacine—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000178	0.003	CbGpPWpGaD
Guanfacine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000177	0.00072	CcSEcCtD
Guanfacine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000177	0.00072	CcSEcCtD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—SERPINA1—chronic obstructive pulmonary disease	0.000176	0.00296	CbGpPWpGaD
Guanfacine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000171	0.000696	CcSEcCtD
Guanfacine—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000167	0.00282	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000165	0.00279	CbGpPWpGaD
Guanfacine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000164	0.00276	CbGpPWpGaD
Guanfacine—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000161	0.00272	CbGpPWpGaD
Guanfacine—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00016	0.0027	CbGpPWpGaD
Guanfacine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.00016	0.000649	CcSEcCtD
Guanfacine—ADRA2A—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	0.000158	0.00266	CbGpPWpGaD
Guanfacine—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000632	CcSEcCtD
Guanfacine—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000153	0.000623	CcSEcCtD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—TGFB2—chronic obstructive pulmonary disease	0.000153	0.00257	CbGpPWpGaD
Guanfacine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000603	CcSEcCtD
Guanfacine—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000147	0.00248	CbGpPWpGaD
Guanfacine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000146	0.00246	CbGpPWpGaD
Guanfacine—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000583	CcSEcCtD
Guanfacine—ADRA2B—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000142	0.0024	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000142	0.00239	CbGpPWpGaD
Guanfacine—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000141	0.00237	CbGpPWpGaD
Guanfacine—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000139	0.00235	CbGpPWpGaD
Guanfacine—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000138	0.00056	CcSEcCtD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000137	0.0023	CbGpPWpGaD
Guanfacine—Rash—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000556	CcSEcCtD
Guanfacine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000555	CcSEcCtD
Guanfacine—Headache—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000552	CcSEcCtD
Guanfacine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000133	0.00223	CbGpPWpGaD
Guanfacine—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000523	CcSEcCtD
Guanfacine—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000129	0.00217	CbGpPWpGaD
Guanfacine—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000127	0.00214	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	0.00012	0.00201	CbGpPWpGaD
Guanfacine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000119	0.002	CbGpPWpGaD
Guanfacine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000117	0.00198	CbGpPWpGaD
Guanfacine—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000117	0.00197	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000117	0.00197	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000116	0.00196	CbGpPWpGaD
Guanfacine—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000116	0.00195	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000108	0.00182	CbGpPWpGaD
Guanfacine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000107	0.0018	CbGpPWpGaD
Guanfacine—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000107	0.0018	CbGpPWpGaD
Guanfacine—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000105	0.00177	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000105	0.00176	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000104	0.00175	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—TGFB2—chronic obstructive pulmonary disease	0.000104	0.00175	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	9.97e-05	0.00168	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	9.91e-05	0.00167	CbGpPWpGaD
Guanfacine—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	9.77e-05	0.00165	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—APIP—chronic obstructive pulmonary disease	9.67e-05	0.00163	CbGpPWpGaD
Guanfacine—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	9.64e-05	0.00162	CbGpPWpGaD
Guanfacine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	9.64e-05	0.00162	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—HDAC2—chronic obstructive pulmonary disease	9.3e-05	0.00157	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	9.16e-05	0.00154	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	9.07e-05	0.00153	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	9.05e-05	0.00153	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	9.04e-05	0.00152	CbGpPWpGaD
Guanfacine—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	8.98e-05	0.00151	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	8.92e-05	0.0015	CbGpPWpGaD
Guanfacine—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	8.91e-05	0.0015	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	8.89e-05	0.0015	CbGpPWpGaD
Guanfacine—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	8.86e-05	0.00149	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	8.84e-05	0.00149	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	8.83e-05	0.00149	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	8.81e-05	0.00148	CbGpPWpGaD
Guanfacine—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	8.79e-05	0.00148	CbGpPWpGaD
Guanfacine—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	8.51e-05	0.00143	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	8.48e-05	0.00143	CbGpPWpGaD
Guanfacine—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	8.4e-05	0.00141	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—PLAUR—chronic obstructive pulmonary disease	8.38e-05	0.00141	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	8.38e-05	0.00141	CbGpPWpGaD
Guanfacine—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	8.19e-05	0.00138	CbGpPWpGaD
Guanfacine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	8.11e-05	0.00137	CbGpPWpGaD
Guanfacine—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	8.08e-05	0.00136	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	8.04e-05	0.00135	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	7.97e-05	0.00134	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	7.94e-05	0.00134	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—TGFB2—chronic obstructive pulmonary disease	7.87e-05	0.00132	CbGpPWpGaD
Guanfacine—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	7.76e-05	0.00131	CbGpPWpGaD
Guanfacine—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	7.66e-05	0.00129	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	7.57e-05	0.00127	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	7.3e-05	0.00123	CbGpPWpGaD
Guanfacine—ADRA2B—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	7.12e-05	0.0012	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	7.06e-05	0.00119	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—HDAC2—chronic obstructive pulmonary disease	7.06e-05	0.00119	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	7.05e-05	0.00119	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	6.97e-05	0.00117	CbGpPWpGaD
Guanfacine—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.95e-05	0.00117	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	6.95e-05	0.00117	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	6.87e-05	0.00116	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	6.85e-05	0.00115	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	6.77e-05	0.00114	CbGpPWpGaD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	6.7e-05	0.00113	CbGpPWpGaD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	6.68e-05	0.00113	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.4e-05	0.00108	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—PLAUR—chronic obstructive pulmonary disease	6.36e-05	0.00107	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	6.25e-05	0.00105	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GC—chronic obstructive pulmonary disease	6.23e-05	0.00105	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	6.1e-05	0.00103	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	6.07e-05	0.00102	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	6.05e-05	0.00102	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—MMP1—chronic obstructive pulmonary disease	5.99e-05	0.00101	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—PLAU—chronic obstructive pulmonary disease	5.88e-05	0.000991	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.88e-05	0.00099	CbGpPWpGaD
Guanfacine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.8e-05	0.000976	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.79e-05	0.000976	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	5.66e-05	0.000953	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	5.57e-05	0.000939	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.54e-05	0.000933	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—NOS2—chronic obstructive pulmonary disease	5.4e-05	0.00091	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.4e-05	0.00091	CbGpPWpGaD
Guanfacine—ADRA2A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	5.4e-05	0.00091	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.36e-05	0.000902	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	5.35e-05	0.000901	CbGpPWpGaD
Guanfacine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.33e-05	0.000897	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.29e-05	0.000891	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.12e-05	0.000862	CbGpPWpGaD
Guanfacine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.05e-05	0.000851	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	5.04e-05	0.000849	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	4.88e-05	0.000823	CbGpPWpGaD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	4.61e-05	0.000776	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	4.58e-05	0.000771	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	4.55e-05	0.000766	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—MMP1—chronic obstructive pulmonary disease	4.55e-05	0.000766	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—ALB—chronic obstructive pulmonary disease	4.54e-05	0.000765	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.54e-05	0.000764	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	4.51e-05	0.000759	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	4.5e-05	0.000758	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—PLAU—chronic obstructive pulmonary disease	4.46e-05	0.000752	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	4.45e-05	0.00075	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	4.41e-05	0.000743	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—NOS3—chronic obstructive pulmonary disease	4.34e-05	0.000732	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.31e-05	0.000726	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	4.31e-05	0.000726	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.29e-05	0.000723	CbGpPWpGaD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	4.23e-05	0.000712	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.14e-05	0.000697	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	4.12e-05	0.000694	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.1e-05	0.000691	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	4.1e-05	0.000691	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—NOS2—chronic obstructive pulmonary disease	4.1e-05	0.000691	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	4.09e-05	0.000689	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.06e-05	0.000684	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	4.02e-05	0.000678	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.94e-05	0.000664	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.83e-05	0.000644	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.74e-05	0.00063	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.58e-05	0.000603	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.47e-05	0.000585	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	3.45e-05	0.000581	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—ALB—chronic obstructive pulmonary disease	3.45e-05	0.00058	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.42e-05	0.000576	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.4e-05	0.000573	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GCLC—chronic obstructive pulmonary disease	3.36e-05	0.000567	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—NOS3—chronic obstructive pulmonary disease	3.3e-05	0.000555	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.27e-05	0.000551	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.27e-05	0.000551	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	3.27e-05	0.000551	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.15e-05	0.000531	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—VEGFA—chronic obstructive pulmonary disease	3.13e-05	0.000527	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.1e-05	0.000523	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—CTGF—chronic obstructive pulmonary disease	3.07e-05	0.000517	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.99e-05	0.000504	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.98e-05	0.000502	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.93e-05	0.000494	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—TGFB1—chronic obstructive pulmonary disease	2.87e-05	0.000484	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.83e-05	0.000476	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.73e-05	0.00046	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.72e-05	0.000457	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.7e-05	0.000456	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	2.65e-05	0.000447	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.47e-05	0.000416	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.44e-05	0.00041	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.42e-05	0.000407	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.41e-05	0.000406	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.39e-05	0.000403	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	2.38e-05	0.000401	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	2.37e-05	0.0004	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—TP53—chronic obstructive pulmonary disease	2.36e-05	0.000398	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.36e-05	0.000397	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.33e-05	0.000392	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.22e-05	0.000375	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.22e-05	0.000374	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.21e-05	0.000372	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.2e-05	0.00037	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.2e-05	0.00037	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	2.18e-05	0.000367	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	2.17e-05	0.000366	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	2.17e-05	0.000366	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.17e-05	0.000365	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.11e-05	0.000356	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.06e-05	0.000346	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.05e-05	0.000346	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.03e-05	0.000341	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2e-05	0.000338	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.98e-05	0.000334	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.97e-05	0.000331	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.85e-05	0.000311	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.83e-05	0.000309	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.83e-05	0.000308	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—TP53—chronic obstructive pulmonary disease	1.79e-05	0.000302	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.68e-05	0.000283	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.67e-05	0.000282	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.67e-05	0.000281	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.65e-05	0.000278	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.62e-05	0.000272	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.6e-05	0.00027	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.54e-05	0.00026	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.54e-05	0.000259	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.52e-05	0.000257	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.5e-05	0.000253	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.49e-05	0.000251	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.47e-05	0.000248	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.46e-05	0.000245	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.45e-05	0.000244	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.43e-05	0.000241	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.4e-05	0.000236	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	1.4e-05	0.000235	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	1.34e-05	0.000225	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.33e-05	0.000224	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.31e-05	0.00022	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.31e-05	0.00022	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.24e-05	0.000209	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.23e-05	0.000207	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.21e-05	0.000203	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.18e-05	0.000199	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.17e-05	0.000197	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.12e-05	0.000188	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.06e-05	0.000179	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.01e-05	0.000169	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.91e-06	0.000167	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.91e-06	0.000167	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	9.9e-06	0.000167	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	9.74e-06	0.000164	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	9.55e-06	0.000161	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	9.47e-06	0.000159	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.42e-06	0.000159	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.24e-06	0.000156	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	9.02e-06	0.000152	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.96e-06	0.000151	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.76e-06	0.000147	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	8.63e-06	0.000145	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.05e-06	0.000136	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	8.02e-06	0.000135	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.39e-06	0.000124	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	7.34e-06	0.000124	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.24e-06	0.000122	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.08e-06	0.000102	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	5.95e-06	0.0001	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	5.69e-06	9.59e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.57e-06	9.38e-05	CbGpPWpGaD
